Use of Negative Pressure Wound Therapy for Cesarean Patients with Obesity



Evaluating clinical outcomes and budget impact at a quaternary care hospital


IC4

Nisha Almeida, PhD, Eva Suarthana, MD, PhD, Thiphavone Oudanonh, MSc Health Technology Assessment Unit of the McGill University Health Centre

What is Negative Pressure Wound Therapy?

- A wound-healing technology that creates a vacuum-sealed environment to improve healing and reduce the risk of infection.
- The two commonly available devices differ by the level of negative pressure used: -80 mmHg or -125 mmHg.
- **Policy question:** Should NPWT be used in patients with a BMI >30 kg/m² who undergo cesarean section at the MUHC?

Methods				
	Meta-analysis of 10	O randomized controlled trials		
	Population	Pregnant patients with obesity (BMI>30kg/m²) undergoing cesarean		
	Intervention	Negative pressure wound therapy (NPWT)		
	Comparator	Standard dressing		
	Outcomes	Surgical site infections, wound complications, hospital readmissions, and reoperations		



	Effectiveness	
Linical	FTTOCTIVONOCC	
Cillica	LIICCHVCHC33	

	Surgical Site Infections	21% reduction (RR=0.79, 95% CI: 0.66, 0.95) Moderate quality evidence
-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\	Wound Complications	Inconclusive (RR=0.90, 95% CI: 0.73, 1.09)
		Low quality evidence
	Hospital Readmissions	No evidence of benefit (RR=1.41, 95% CI: 0.88, 2.27)
		Low quality evidence
	Pressure Level	No significant difference in outcomes

Low quality evidence

(-80 vs -125mmHg)

Budget Impact

A	Burden of Illness	Post-cesarean SSI rate at MUHC ranges from 1.5% to 2.8% over past 5 years
	Cases prevented if NPWT used	3 to 5 SSI cases annually
	Budget impact	Device cost: \$200 Cost for 200 patients: \$40,000/year
	Incremental cost-	\$11,173 to prevent one additional

surgical site infection

Conclusions

- Given the very low rate of surgical site infection post-caesarean section at the MUHC;
- Given that there is no evidence of effectiveness of the device on more serious complications and readmissions;
- The opportunity for impact on clinical benefit and cost savings is minimal.

effectiveness ratio